secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAGENICS INC (OGEN)
CIK:        0001174940
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0001493152-24-031163
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oragenics: concussion drug ONP-002 shows no genotoxicity in animal study; Phase II planned
--------------------------------------------------------------------------------

- ONP-002 completed in vivo micronucleus assay; no evidence of genetic mutations or DNA damage across low, medium, high doses.
- Study conducted under GLP conditions with VivoPharm; supports safety for planned Phase II clinical trial for concussion.
- Company previously reported safety margin in two-species tox and cardiac safety (GLP hERG); now genotoxicity cleared.
- Concussion affects ~69M annually globally; post-concussion symptoms cause long-term disability in up to 20% of patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1174940/000149315224031163/0001493152-24-031163-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1174940/000149315224031163/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-031163

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer